Abstract Library

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4332 Efficacy of SIRT radioembolisation of liver metastases of neuroendocrine tumours (NETs): A single institution experience

Introduction: Majority of NET patients develop liver metastases (NET-LM). Improved treatment of NET-LM may prolong survival. In case of liver-dominant metastatic disease, local radionuclide treatment using microspheres could be considered.

Conference:

Presenting Author: Kropinska A

Authors: Kropinska A, Gola M, Sygula A, Hamm M, Ledwon A,

Keywords: SIRT, radioembolisation, neuroendocrine tumour, liver metastasis,

#3914 Mediastinal neuroendocrine tumor with heart metastasis response to immunotherapy

Introduction: Mediastinal tumor is unusual, representing 0.2 to 1.5% of tumors in human, mediastinal neuroendocrine tumor even rare.

Conference:

Presenting Author: Cai W

Authors: Cai W, Chen G, Ge W, Hu H,

Keywords: Mediastiunum, NET G2, Immunotherapy,

#3037 Effects of Debulking Surgery, Transarterial Embolisation (TAE) and Transarterial Chemoembolisation (TACE) on Quality of Life in Patients with Metastatic Ileal and Pancreatic Neuroendocrine Tumours (NETs)

Introduction: Debulking surgery, TAE and TACE procedures are undertaken in patients with metastatic NETs. Reducing the physical burden of disease may prolong survival and can improve the quality of life of patients. However, there is only limited quality of life data available after surgery despite the fact that is has been used routinely for many years.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sinclair A, Tanno L, Jarvis E, Ramsey E, Naheed S,

Keywords: Quality of Life, Debulking Surgery, TAE, TACE, Metastatic, NETs,

#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours

Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Patel K

Authors: Patel K, Nahar A, Elhassan Y, Shah T, Ayuk J,

Keywords: Somatostatin analogues, Diabetes, Neuroendocrine tumour, HbA1c, BMI,